Hostname: page-component-7bb8b95d7b-cx56b Total loading time: 0 Render date: 2024-09-27T17:46:27.401Z Has data issue: false hasContentIssue false
  • English
  • Français

P01-166 - Transitioning onto OROS MPH is Associated with Improved Functioning and Quality of Life in Adolescents with ADHD

Published online by Cambridge University Press:  17 April 2020

A. Alfred ,
A. Lindermueller ,
F. Mattejat ,
S. Dichter  and
B. Schaeuble
A. Alfred
Affiliation:
Child and Adolescent Psychiatry, Private Practice, Munich, Germany
A. Lindermueller
Affiliation:
Child and Adolescent Psychiatry, Private Practice, Munich, Germany
F. Mattejat
Affiliation:
Dept. of Child and Adolescent Psychiatry, University of Marburg, Marburg, Germany
S. Dichter
Affiliation:
Janssen Cilag GmbH, Neuss, Germany
B. Schaeuble
Affiliation:
EMEA Medical Affairs, Janssen Cilag GmbH, Neuss, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

To explore functionality and quality of life outcomes in adolescents with ADHD transitioning from IR MPH, ER MPH or ATX onto PR OROS MPH.

Methods

Pooled analyses of two similar 12 week open label, flexible dose, non-interventional trials exploring outcomes in adolescents with ADHD (ICD-10) transitioning from either IR / ER MPH, or Atomoxetine onto PR OROS MPH. Connor's parents rating scale (CPRS), children's global assessment scale (CGAS) and quality of life (ILC) were measured.

Results

186 adolescents (84.4% boys; median age 14yrs) were analyzed. Starting dose of OROS MPH was based on clinical judgment. Median dose of PR OROS MPH at baseline and endpoint was 36mg/day. Functionality based on C-GAS as well as burden of disease scores measured in parents and adolescents improved at endpoint (p< 0.001). 80% girls and 67% of boys achieved an at least 30% reduction on CPRS. ILC-LQ0-28 in adolescents and their care givers improved (p< 0.05). 56 adolescents (30,1%) experienced at least one treatment emergent adverse event (AEs≥4% were insomnia (4,8%), headache (3,7%), muscle twitches (3,2%).

Conclusion

Adolescents with ADHD transitioning onto PR OROS MPH showed clinically relevant improvement in daily functioning and quality of life aspects. Burden of disease in patients and their care givers was lowered.

Type
Child and adolescent psychiatry
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E372
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.